Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Eicosapentaenoic Acid on Molecular, Metabonomics and Intestinal Microbiota Changes, in Subjects With Long-standing Inflammatory Bowel Disease

Trial Profile

Effects of Eicosapentaenoic Acid on Molecular, Metabonomics and Intestinal Microbiota Changes, in Subjects With Long-standing Inflammatory Bowel Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eicosapentaenoic acid (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacodynamics
  • Acronyms EPAUC
  • Most Recent Events

    • 17 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jun 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 23 Oct 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Apr 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top